TheraRadar
← Back
Data updated: Jun 28, 2026

CSPC OUYI

Generics
GastroenterologyInfectious DiseaseOncology Execution: Needs Improvement

CSPC OUYI is a generic drug manufacturer focused on Gastroenterology, Infectious Disease, Oncology. Key products include CONJUPRI.

2005
Since
13
Drugs
-
Trials
1
New Drugs (2yr)

CSPC OUYI at a Glance

  • Growing R&D activity with 9 trials in last 2 years
  • Fast trial execution (17 months median completion)

CSPC OUYI's Key Drugs

CSPC OUYI's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

CSPC OUYI's Recent FDA Approvals

CSPC OUYI secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

DULOXETINE HYDROCHLORIDE NDA
2026-02-27
duloxetine hydrochloride

CSPC OUYI's Therapeutic Areas

CSPC OUYI's approved drugs and pipeline span 5 therapeutic areas, led by Gastroenterology and Infectious Disease. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Gastroenterology 27%
2 drugs Phase 2: 1
Infectious Disease 24%
2 drugs
Oncology 22%
0 drugs Phase 3: 1 Phase 2: 3 Phase 1: 1
Dermatology 16%
1 drugs Phase 2: 1
Respiratory 12%
1 drugs

CSPC OUYI Pipeline Snapshot

CSPC OUYI has 7 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 5 Phase 2 and 1 Phase 1.

1
Phase 3
5
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Gastroenterology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 2/8 completed
  • • Speed: 17 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges